See the latest news and media coverage for MyOme. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical whole genome analysis platform
myome.comLast updated
In short: MyOme expanded its genomic capabilities through the launch of a unified DNA and methylation platform and a strategic partnership with Natera.
The study, published in AJPC, shows integrated models yield more consistent risk estimates than either approach alone, as guidelines now recognize polygenic risk as an enhancer.
The multi-omic approach integrates epigenetic signatures to resolve complex rare disease cases.
The deal supports MyOme's Proactive Health Trial, which aims to show cost savings from whole-genome sequencing and AI risk models.
The test identifies men at elevated genetic risk, enabling earlier detection and personalized prevention.
In a major step toward expanding patient access, MyOme is highlighting its strategic partnership with Natera (NASDAQ: NTRA) to launch Zenith™ powered by MyOme. Zenith...
SAN FRANCISCO and MENLO PARK, Calif., Dec. 15, 2025 /PRNewswire/ -- Thatch, a modern benefits platform that helps employers offer personalized, cost-effective healthcare through Individual...
/PRNewswire/ -- MyOme, a leading clinical whole-genome testing and polygenic risk modeling (PRS) company, today announced the launch of its Prostate Cancer...
/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and...
Track MyOme and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to MyOme and other trending companies.